Association between gene polymorphism and depression in Parkinson's disease: A case-control study

Zheng, Jinhua; Yang, Xinglong; Zhao, Quanzhen; Tian, Sijia; Huang, Hongyan; Chen, Yalan; Xu, Yanming

doi:10.1016/j.jns.2017.02.001

Cited by 19 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Ragab and colleagues found the prevalence at 47.5% [27]. Across literature, several studies [7,[28][29][30][31] found the prevalence of depression in PD was ranging from 32.6 to 41%. A systematic review conducted by Reijnders et al reported that 17% and 22% of PD patients had MDD and minor depression, respectively [32].…”

Section: Discussionmentioning

confidence: 99%

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Khedr

Abdel‐Rahman

Elserogy

et al. 2020

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Depression and anxiety are non-motor symptoms of Parkinson’s disease (PD) that are often overlooked and underrated. This study aimed to highlight the frequency and risk factors of depression and anxiety among subjects with PD. Methods Sixty-four patients with PD who were diagnosed according to United Kingdom Parkinson’s Disease Society (UKPDS) Brain Bank Criteria and 50 sex- and age-matched healthy control subjects are evaluated for depression and anxiety. PD severity and staging were assessed using Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr scale. Depression and anxiety were diagnosed using DSM-IV TR criteria and scored using Hamilton Depression and Hamilton Anxiety Rating Scales (HAM-D and HAM-A). The World Health Organization Quality of Life (WHOQOL)-BREF was used to assess impact of depression and anxiety on quality of life. Results 31.25% of patients with PD had depression while 40.6% of patients had anxiety disorder. Depression was higher in females and patients with history of depression and low socioeconomic status (SES). Anxiety was common in young patients and those who had history of anxiety. Overlap between depression and anxiety was recorded in 23.4%. Total UPDRS and Hoehn and Yahr scale accounted for 33.4% of variance for depression. Total UPDRS and earlier age of onset accounted for 39% of variance for anxiety. Advanced disease stage and severity were independent predictors for depression while disease severity and younger age of onset were the main predictors for anxiety. Depression and anxiety have a negative impact on the overall quality of life of PD patients especially on physical and psychosocial domains. Conclusion Depression and anxiety are relatively common in PD. Female gender, low SES, and history of depression were the main risk factors for developing depression. Young age and history of anxiety were risk factors for anxiety. Both had negative impact on quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Khedr

Abdel‐Rahman

Elserogy

et al. 2020

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

show abstract

“…Interestingly, serotoninergic neurons are progressively lost in PD, which is implicated both in motor and non-motor manifestations of PD [72]. Moreover, polymorphisms in TPH2 are associated with addictive behaviors [73] and depression [74] in PD patients. Additionally, Tph2 KO mice, which have serotonin deficiency, present with systemic oxidative stress and lipidomic abnormalities [75], and swallowing dysfunction [76].…”

Section: Discussionmentioning

confidence: 99%

Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson’s Disease

Brouwers

Wieringa

Martens³

2020

Cells

View full text Add to dashboard Cite

Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons from the substantia nigra (SN) that project to the dorsal striatum (caudate-putamen). To better understand the molecular mechanisms underlying PD, we performed combined lipid profiling and RNA sequencing of SN and putamen samples from PD patients and age-matched controls. SN lipid analysis pointed to a neuroinflammatory component and included elevated levels of the endosomal lipid Bis (Monoacylglycero)Phosphate 42:8, while two of the three depleted putamen lipids were saturated sphingomyelin species. Remarkably, we observed gender-related differences in the SN and putamen lipid profiles. Transcriptome analysis revealed that the top-enriched pathways among the 354 differentially expressed genes (DEGs) in the SN were “protein folding” and “neurotransmitter transport”, and among the 261 DEGs from putamen “synapse organization”. Furthermore, we identified pathways, e.g., “glutamate signaling”, and genes, encoding, e.g., an angiotensin receptor subtype or a proprotein convertase, that have not been previously linked to PD. The identification of 33 genes that were common among the SN and putamen DEGs, which included the α-synuclein paralog β-synuclein, may contribute to the understanding of general PD mechanisms. Thus, our proof-of-concept data highlights new genes, pathways and lipids that have not been explored before in the context of PD.

show abstract

“…BDNF (rs6265) variant has been associated with depression in people with PD, after accounting for the effects of potential confounders such as gender, disease progression and motor symptoms (p = 0.046) (Cagni et al, 2017). TEF TT genotype (Hua et al, 2012), CRY1 CC genotype (Hua et al, 2012), SLC6A15 (rs1545843) (Zheng et al, 2017) and TPH2 (rs78162420) (Zheng et al, 2017) have been associated with depression in people with PD, and these findings have not been replicated so far. Moreover, people with PD carrying SNCA Rep1 (CA)12/12 genotype reportedly has a reduced risk of depression (p = 0.02) (Dan et al, 2016).…”

Section: Supplementary Informationmentioning

confidence: 99%

“…Fourteen studies studied PD service users, who are carriers of LRRK2 variants (rs34637584, rs33939927, rs11564148 and rs34778348). Other genes that have been investigated included SNCA (Zheng et al, 2017), APOE, BDNF (rs6265), SLC6A4, COMT (Val158Met) and MAPT. Only 26 (60.5%) included studies have had sample sizes above 100.…”

Section: Fig 1 Presents the Preferred Reporting Items For Systematicmentioning

confidence: 99%

Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson’s disease

D’Souza

Rajkumar

2019

Acta Neuropsychiatr.

View full text Add to dashboard Cite

Objective:Cognitive impairment and depression are among the most prevalent and most disabling non-motor symptoms in Parkinson’s disease (PD). The genetic factors that are associated with these symptoms remain uncertain. This systematic review aims to summarise the prevailing evidence from all genetic association studies investigating the genetic variants associated with cognitive impairment and depressive symptoms in people with PD.Method:A systematic review using five online databases: PubMed, PsycINFO, CINAHL, EMBASE and OpenGrey (PROSPERO protocol: CRD42017067431). We completed the quality assessment using the Q-Genie tool.Results:2353 articles were screened, and 43 articles were found to be eligible to be included. A meta-analysis of studies investigating LRRK2 rs34637584 confirmed that the minor allele carriers had significantly less cognitive impairment (p = 0.015). Further meta-analyses showed that GBA variants rs76763715 (p < 0.001) and rs421016 (p = 0.001) were significantly associated with more cognitive impairment in people with PD. Minor alleles of GBA variants rs76763715, rs421016, rs387906315 and rs80356773 were associated with more depressive symptoms in PD. Moreover, APOE ε4 allele has been associated with more cognitive impairment in PD. BDNF (rs6265) and CRY1 (rs2287161) variants have been associated with more depressive symptoms in people with PD.Conclusions:PD carriers of GBA variants are at high risk for cognitive decline and depression. Screening for these variants may facilitate early identification and effective management of these non-motor symptoms. The molecular mechanisms underlying favourable cognitive functioning in LRRK2 rs34637584 variant carriers warrant further investigation.

show abstract

Association between gene polymorphism and depression in Parkinson's disease: A case-control study

Cited by 19 publications

References 29 publications

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life

Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson’s Disease

Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson’s disease

Contact Info

Product

Resources

About